SCHEMBL3759562

SCHEMBL3759562

[c]1ncccc1-c1nccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
KDM4E B2RXH2 4/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 2/20 0.44
GLA P06280 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PLAU P00749 2/20 0.43
CYP2A6 P11509 1/20 0.43
F12 P00748 1/20 0.43
NCF1 P14598 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
BACE1 P56817 1/20 0.43
GPR55 Q9Y2T6 1/20 0.41
MAPK1 P28482 3/20 0.39
HTR2C P28335 2/20 0.39
CYP3A4 P08684 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8117632 0.78 MAPT (0.43) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL3137107 0.77 MAPT (0.45) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL199273 0.77 PLAU (0.60) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL29923403 0.77 PLAU (0.60) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL1115099 0.75 NISCH (0.41) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL30522769 0.75 PLAU (0.58) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL303629 0.73 KDM4E (0.42) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL3278102 0.73 MAPT (0.45) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL12223316 0.73 PLAU (0.56) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL13978866 0.73 PLAU (0.56) MAPTKDM4ENPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
EP-0001054-A2 2-Pyridyl-1,4-dihydropyridine derivatives, methods for their preparation and their pharmaceutical use BAYER AG (DE) 1979-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAPT 790/4885KDM4E 1014/4885NPC1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.